Septin-7 Antibody, Cell-Binding Assay, Serum
Use
Detecting septin-7 IgG by cell-binding assay using serum specimens. The presence of septin-7 IgG is associated with various neurological phenotypes, including encephalopathy, myelopathy, encephalomyelopathy, painful myelopolyradiculopathy, and episodic ataxia. It is also associated with psychiatric symptoms and cancer. The test helps confirm the diagnosis of autoimmune disease of the central nervous system when septin-7 IgG is detected via cell-binding assay.
Special Instructions
Not provided.
Limitations
Negative results for septin-7 IgG by cell-binding assay do not definitively exclude neurological autoimmunity or cancer. It is vital for proper diagnosis that a comprehensive clinical assessment is conducted alongside serological testing.
New York Approved
Methodology
Other (Cell-Binding Assay)
Biomarkers
Septin-7
Protein
LOINC Codes
- 101467-9 - Septin-7 IgG SerPl Ql CBA IFA
- 101467-9 - Septin-7 IgG SerPl Ql CBA IFA
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Storage Instructions
Refrigerated (preferred) - 28 days; Ambient - 72 hours; Frozen - 28 days
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |